The Problem
Traumatic brain injury (TBI) affects 1 in 4 people in their lifetime, striking more often than breast cancer, ovarian cancer, AIDS, and multiple sclerosis combined. As the leading cause of death and disability for individuals under 45, TBI leaves lasting impacts with no FDA-approved drugs to address its long-term effects.
The Solution
TheBIRF has developed the Traumatic Brain Injury Treatment Accelerator Program (TBITXL) which brings together the worlds brightest neuroscientists to solve the world’s toughest problem.
At its core, TBITXL aims to address critical unmet needs in TBI drug development by
incorporating the voice of patients, biotech companies, academia, & regulatory agencies. Its primary goal is to overcome the challenges often encountered in collaborative efforts between these entities.
The Mission
To decrease the cost and improve the rate and effectiveness of successful traumatic brain injury drug launches.
The Drive
TheBIRF and its partners are laser-focused on enhancing our comprehension of
neurodegenerative pathways that hold therapeutic potential. If you would like to work with us to develop the first medication to treat traumatic brain injuries, contact our team below.